Physician profile
William H Opferman
NPI 1659420818
$4,091.02
in general payments reported to CMS, 2019-2025
11 companies · $582 in 2025
The $582 reported for 2025 was more than what 81% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,899 · 2020: $183 · 2021: $259 · 2022: $392 · 2023: $399 · 2024: $378 · 2025: $582.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,359.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,358.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb, A Division of Bausch Health US, LLC | $1,850.94 | 2019-2020 | |
| Coopervision INC. | $704.40 | 2021-2025 | Myday Contact Lens, Misight Contact Lens, Clariti Contact Lens |
| Bausch & Lomb Americas INC. | $381.35 | 2022-2025 | Miebo, Xiidra, Infuse |
| Alcon Vision LLC | $291.88 | 2019-2025 | Eysuvis, Tryptyr, Rocklatan |
| Johnson & Johnson Vision Care, INC. | $271.92 | 2020-2024 | |
| Glaukos Corporation | $255.17 | 2024-2025 | Photrexa Viscous and Photrexa, Photrexa |
| Tarsus Pharmaceuticals, INC. | $93.10 | 2024-2025 | Xdemvy |
| Allergan, INC. | $85.34 | 2022 | |
| Sun Pharmaceutical Industries INC. | $83.85 | 2023-2025 | Cequa |
| Oyster Point Pharma, INC. | $57.08 | 2023-2024 | Tyrvaya, Ryzumvi |
| Abb Con-Cise Optical Group LLC | $15.99 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Opferman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.